Spastic Paraplegia 89 (SPG89): A Patient Guide
At a Glance
SPG89 is an ultra-rare inherited condition caused by AMFR mutations that leads to progressive leg stiffness and weakness. There is no cure yet, but physical therapy, stretching, orthotics, and coordinated rehabilitation can help children maintain movement, comfort, and participation.
Spastic Paraplegia 89 (SPG89) is an ultra-rare genetic condition that primarily affects the way the brain communicates with the muscles in the legs. As a form of Hereditary Spastic Paraplegia (HSP), it is characterized by spasticity—a persistent stiffness and tightness in the lower limbs—alongside muscle weakness. This occurs because of mutations in the AMFR gene, which disrupt the internal health of the long nerves that control movement. Because it is inherited in an autosomal recessive manner, a child typically inherits a mutated copy of the gene from each parent, who are usually unaffected carriers themselves [1].
The way SPG89 behaves can vary significantly from one child to another, and because the condition is so rare, it is incompletely characterized. In its “pure” clinical presentation, the symptoms are mostly limited to the legs, affecting a child’s gait and balance. In “complex” presentations, the condition may also involve developmental delays or mild learning challenges. While SPG89 is a progressive condition, meaning the stiffness can increase over time, the exact rate of progression and long-term outcomes for an individual child cannot be reliably predicted from the diagnosis alone [2]. Understanding the specific genetic nature of your child’s condition through definitive testing is a vital first step, as it allows your medical team to move past the “diagnostic odyssey” and focus on a targeted care plan [3].
Living with SPG89 is a journey of proactive management and adaptation. Because there is currently no cure for the underlying genetic mutation, the goal of treatment is to manage symptoms and maximize your child’s physical function and comfort. This is best achieved through a multidisciplinary care team—a group of specialists including neurologists, physical therapists, and rehabilitation doctors who work together to support every aspect of your child’s development [4]. Regular, individualized physical therapy, consistent stretching, and the use of supportive tools like orthotics are the cornerstones of maintaining mobility and preventing complications [5].
What is Known and What is Still Uncertain
- Known: SPG89 is caused by mutations in the AMFR gene and causes progressive spasticity and weakness.
- Uncertain: The adult outcomes, exact rate of progression, and frequency of specific symptoms are not fully established due to the small number of reported cases globally.
- Known: Physical therapy and rehabilitation can improve function, comfort, and participation in daily life.
- Uncertain: There is currently no established disease-modifying therapy that stops the genetic progression.
While a diagnosis of such a rare condition can feel overwhelming, it also provides a roadmap for support. By focusing on symptomatic care and staying connected with a dedicated team of experts, you can play a central role in protecting your child’s quality of life. Research into the AMFR gene and its role in the nervous system is ongoing, and every child’s story contributes to a growing global understanding of this condition [1]. Your family is not just navigating a diagnosis; you are part of a small but dedicated community working toward a future of better support and clearer answers.
Important Safety Note: Sudden loss of strength, rapid regression of skills, fever with urinary symptoms, inability to urinate, or severe new pain are not typical slow progression and require prompt medical attention.
In this guide
6 chapters
Understanding the SPG89 Diagnosis
Learn what an SPG89 diagnosis means for your child, including AMFR gene mutations, autosomal recessive inheritance, symptoms, and supportive care options.
Symptoms and Disease Progression of SPG89
Learn about SPG89 (spastic paraplegia 89): walking changes, stiffness, weakness, developmental changes, possible bladder symptoms, progression, and contractures.
Biology & Getting the Right Diagnosis
Learn how SPG89 affects nerve cells, how AMFR genetic testing confirms diagnosis, what MRI can show, and which treatable conditions may mimic it in children.
Standard of Care Treatment
Learn how SPG89 treatment supports mobility and comfort with physical therapy, spasticity medicines, injections, orthotics, and selected advanced options.
Day-to-Day Management & Surveillance
Learn how to manage SPG89 day to day, including stretching, fall prevention, bladder and bowel monitoring, school support, and when to seek care for your child.
Building Your Care Team & First Visit Prep
Learn how to build a care team for SPG89 and prepare for the first specialist visit, including genetic reports, MRI records, milestone history, and questions.
Common questions in this guide
What causes SPG89, and how is it passed from parents to children?
What symptoms might a child with SPG89 develop?
Does SPG89 get worse over time, and can doctors predict my child’s future?
Is there a cure or treatment that stops SPG89?
How can physical therapy help a child with SPG89?
When should I seek urgent medical help for a child with SPG89?
Get notified when new evidence is published on spastic paraplegia 89, autosomal recessive.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (5)
- 1
AMFR dysfunction causes autosomal recessive spastic paraplegia in human that is amenable to statin treatment in a preclinical model.
Deng R, Medico-Salsench E, Nikoncuk A, et al.
Acta neuropathologica 2023; (146(2)):353-368 doi:10.1007/s00401-023-02579-9.
PMID: 37119330 - 2
Childhood-onset hereditary spastic paraplegia: at the crossroads between neurodevelopment and neurodegeneration.
Espasandin-Hueter N, Salazar-Villacorta A, Escudero JM, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2026; (65()):50-65 doi:10.1016/j.ejpn.2026.10.002.
PMID: 42976539 - 3
Increased Diagnostic Yield of Spastic Paraplegia with or Without Cerebellar Ataxia Through Whole-Genome Sequencing.
Kim A, Kumar KR, Davis RL, et al.
Cerebellum (London, England) 2019; (18(4)):781-790 doi:10.1007/s12311-019-01038-0.
PMID: 31104286 - 4
French guidelines for the diagnosis and management of pure hereditary spastic paraplegia.
Mania-Pâris L, Ewenczyk C, Nicolas G, et al.
Revue neurologique 2025; (181(6)):471-482 doi:10.1016/j.neurol.2025.05.001.
PMID: 40450402 - 5
The therapeutic effects of physical treatment for patients with hereditary spastic paraplegia: a narrative review.
Di Ludovico A, Ciarelli F, La Bella S, et al.
Frontiers in neurology 2023; (14()):1292527 doi:10.3389/fneur.2023.1292527.
PMID: 38093754
This SPG89 guide is for educational purposes and does not replace medical advice. A neurologist, geneticist, or rehabilitation team can interpret your child’s symptoms and create an individualized care plan.